A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

2009410 citationsJournal Articlehybrid Open Access

Authors

Elizabeth Berry‐Kravis · Rush University Medical Center

David Hessl · University of California Davis Medical Center

Sarah M. Coffey · University of California, Davis

Crystal Hervey · Rush University

Andrea Schneider · University of California, Davis

John M. Yuhas · University of California, Davis

John A. Hutchison

Abstract

Clinically significant adverse effects were not identified in this study of single dose fenobam across the range of dosages utilised. The positive effects seen in animal models of FXS treated with fenobam or other mGluR5 antagonists, the apparent lack of clinically significant adverse effects, and the potential beneficial clinical effects seen in this pilot trial support further study of the compound in adults with FXS.

Topics & Keywords

Genetics and Neurodevelopmental Disorders Autism Spectrum Disorder Research Epigenetics and DNA Methylation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Medical Genetics

Volume 46, Issue 4, pp. 266-271

DOI: 10.1136/jmg.2008.063701

Field-Weighted Citation Impact: 37.98